Lv7
3610 积分 2020-12-06 加入
The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma
1天前
待确认
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
11天前
已完结
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
21天前
已完结
Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?
21天前
已完结
Emerging small molecules for ulcerative colitis: clinical advancements and trial insights
21天前
已完结
Advances and challenges in immunosuppressive antibody drug conjugates
21天前
已完结
Expanding the therapeutic horizon in inflammatory bowel disease: The rise of non-cytokine compounds
21天前
已完结
Emerging small molecules for ulcerative colitis: clinical advancements and trial insights
21天前
已完结
Recent advances in the discovery of small-molecule inhibitors for inflammatory bowel disease therapy
21天前
已完结
Advances and challenges in immunosuppressive antibody drug conjugates
21天前
已完结
皖公网安备34019202002308
